David C Fritzinger

Summary

Affiliation: University of Hawaii
Country: USA

Publications

  1. ncbi Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Dev Comp Immunol 33:105-16. 2009
  2. ncbi Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, HI 96813, USA
    Adv Exp Med Biol 703:151-62. 2010
  3. ncbi Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor
    Brian E Hew
    University of Hawaii Cancer Center, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Toxicon 60:632-47. 2012
  4. ncbi Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Toxicon 56:1198-222. 2010
  5. ncbi Recombinant cobra venom factor
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Mol Immunol 41:191-9. 2004
  6. ncbi Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii 96813, USA
    Curr Pharm Des 13:2916-26. 2007
  7. ncbi Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents
    David C Fritzinger
    Natural Products and Cancer Biology Program, Cancer Research Center of Hawaii, USA
    Hawaii Med J 64:133-4, 137. 2005
  8. ncbi Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, HI 96813, USA
    Adv Exp Med Biol 632:293-307. 2008

Collaborators

Detail Information

Publications8

  1. ncbi Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Dev Comp Immunol 33:105-16. 2009
    ..Such hybrid proteins are important tools to study the structure/function relationships in both C3 and CVF, and these "humanized CVF" proteins may become reagents for therapeutic complement depletion...
  2. ncbi Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, HI 96813, USA
    Adv Exp Med Biol 703:151-62. 2010
    ..Systemic complement depletion with a complement depletor, such as the humanized CVF protein HC3-1496, represents a promising therapeutic concept for patients with wet AMD...
  3. ncbi Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor
    Brian E Hew
    University of Hawaii Cancer Center, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Toxicon 60:632-47. 2012
    ..Interestingly, the structural changes in the individual hybrid proteins differentially affected the molecular functions of the CVF,Bb enzyme such as convertase formation, C3 cleavage, and C5 cleavage...
  4. ncbi Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Toxicon 56:1198-222. 2010
    ..The use of humanized CVF for therapeutic complement depletion in several pre-clinical models of human diseases is also reviewed...
  5. ncbi Recombinant cobra venom factor
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813, USA
    Mol Immunol 41:191-9. 2004
    ....
  6. ncbi Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion
    Carl Wilhelm Vogel
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii 96813, USA
    Curr Pharm Des 13:2916-26. 2007
    ..These human C3 derivatives are "humanized CVF" proteins that represent an attractive biopharmaceutical for therapeutic complement depletion...
  7. ncbi Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents
    David C Fritzinger
    Natural Products and Cancer Biology Program, Cancer Research Center of Hawaii, USA
    Hawaii Med J 64:133-4, 137. 2005
  8. ncbi Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents
    David C Fritzinger
    Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, HI 96813, USA
    Adv Exp Med Biol 632:293-307. 2008
    ..Human C3/CVF hybrid proteins represent a novel class ofbiologicals as potential therapeutic agents in many diseases where complement is involved in the pathogenesis...